Financial Performance Highlights - Net revenues increased by 9.1% (8.0% on a constant currency basis) to $311312000 in Q3 2025 compared to $285468000 in Q3 2024[31] - Adjusted EBITDA increased by 12.2% (11.2% on a constant currency basis) to $164000000 in Q3 2025 compared to $146000000 in Q3 2024[31] - Adjusted EBITDA margin increased by 147 basis points to 52.7% in Q3 2025[25, 31] - Adjusted EPS increased by $0.09 to $0.26 in Q3 2025[25, 31] - Net Leverage Ratio improved to 3.3x as of September 30, 2025, compared to 3.7x as of December 31, 2024[29, 44] Segment Performance - Sterigenics' revenue increased by 9.8% (8.4% on a constant currency basis) in Q3 2025[33] - Nordion's revenue increased by 22.4% (23.6% on a constant currency basis) in Q3 2025[36] - Nelson Labs' revenue decreased by 5.0% (-6.4% on a constant currency basis) in Q3 2025[39] Liquidity and Capital Deployment - Strong liquidity position of $891000000 as of September 30, 2025, with no outstanding borrowings on the revolving line of credit[29, 43] - Executed $75000000 Term Loan repayment in Q3 2025[29] 2025 Outlook - Full-year 2025 net revenue growth is expected to be between 4.5% and 6.0%[52] - Full-year 2025 Adjusted EBITDA growth is expected to be between 6.75% and 7.75%[52]

Q2 2025 Financial Highlights - Net revenues increased by 64% to $294341 million, or 60% on a constant currency basis, compared to Q2 2024[35, 69] - Adjusted EBITDA increased by 98% to $150735 million, or 95% on a constant currency basis, compared to Q2 2024[29, 69] - Adjusted EBITDA margin increased by 156 basis points to 512% compared to Q2 2024[29, 35] - Adjusted EPS increased by $001 to $020 compared to Q2 2024[29, 35] Segment Performance - Sterigenics revenue increased by 105% to $194839 million in Q2 2025[38, 69] - Nordion revenue increased by 29% to $42431 million in Q2 2025[42, 69] - Nelson Labs revenue decreased by 33% to $57071 million in Q2 2025[46, 69] Liquidity and Capital Deployment - Strong liquidity position of $918 million as of June 30, 2025, with no outstanding borrowings on the revolving line of credit[32, 51] - Net Leverage Ratio improved to 35x as of June 30, 2025, compared to 37x as of December 31, 2024[32, 53] Full-Year 2025 Outlook - Net Revenues are expected to increase by 45% to 60%[60] - Adjusted EBITDA is expected to increase by 60% to 75%[60] - Adjusted EPS is expected to be $075 to $082[60]

Financial Performance - Net Revenues increased by 2.6% to $255 million, or 4.4% on a constant currency basis[39, 34] - Adjusted EBITDA increased by 8.8% to $122 million, or 11.2% on a constant currency basis[39, 34] - Adjusted EBITDA margin expanded by 276 basis points to 47.9%[34, 39] - Adjusted EPS increased by $0.01 to $0.14[34, 39] Segment Performance - Sterigenics revenue increased by 1.9% to $170 million, with a segment income increase of 2.5%[43] - Nordion revenue increased by 35.6% to $33 million, with a segment income increase of 61.5%[47] - Nelson Labs revenue decreased by 9.3% to $52 million, but segment income increased by 7.0%[51] Liquidity and Capital Deployment - Strong liquidity position of $715 million as of March 31, 2025, with no outstanding borrowings on the revolving line of credit[36, 55] - Net Leverage Ratio improved to 3.6x as of March 31, 2025[36, 57] - Completed $176 million upsize of the revolving line of credit and extended the facility to April 2030[36, 61] 2025 Outlook - The company expects Net Revenues to increase by 4.0% to 6.0%[64] - The company expects Adjusted EBITDA to increase by 4.5% to 6.5%[64]